PE20221588A1 - Degradador selectivo del receptor de estrogeno - Google Patents

Degradador selectivo del receptor de estrogeno

Info

Publication number
PE20221588A1
PE20221588A1 PE2022000135A PE2022000135A PE20221588A1 PE 20221588 A1 PE20221588 A1 PE 20221588A1 PE 2022000135 A PE2022000135 A PE 2022000135A PE 2022000135 A PE2022000135 A PE 2022000135A PE 20221588 A1 PE20221588 A1 PE 20221588A1
Authority
PE
Peru
Prior art keywords
estrogen receptor
selective estrogen
receptor degrader
chromen
azetidin
Prior art date
Application number
PE2022000135A
Other languages
English (en)
Spanish (es)
Inventor
Ranjan Kumar Pal
Biswajit Samanta
Jayraj Dilipbhai Aradhye
Sandeep Pankajkumar Pathak
Kaushik Dhanjibhai Prajapati
Bhavesh Mohanbhai Panchal
Trinadha Rao Chitturi
Original Assignee
Sun Pharma Advanced Res Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharma Advanced Res Co Ltd filed Critical Sun Pharma Advanced Res Co Ltd
Publication of PE20221588A1 publication Critical patent/PE20221588A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PE2022000135A 2019-07-22 2020-07-22 Degradador selectivo del receptor de estrogeno PE20221588A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201921029554 2019-07-22
PCT/IB2020/056914 WO2021014386A1 (en) 2019-07-22 2020-07-22 Selective estrogen receptor degrader

Publications (1)

Publication Number Publication Date
PE20221588A1 true PE20221588A1 (es) 2022-10-10

Family

ID=71842730

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2022000135A PE20221588A1 (es) 2019-07-22 2020-07-22 Degradador selectivo del receptor de estrogeno

Country Status (15)

Country Link
US (2) US11014915B2 (cg-RX-API-DMAC7.html)
EP (1) EP4003525A1 (cg-RX-API-DMAC7.html)
JP (1) JP2022541938A (cg-RX-API-DMAC7.html)
KR (1) KR20220046586A (cg-RX-API-DMAC7.html)
CN (1) CN114302879A (cg-RX-API-DMAC7.html)
AU (1) AU2020317099A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022001285A2 (cg-RX-API-DMAC7.html)
CA (1) CA3148592A1 (cg-RX-API-DMAC7.html)
CL (1) CL2022000156A1 (cg-RX-API-DMAC7.html)
IL (1) IL290036A (cg-RX-API-DMAC7.html)
MX (1) MX2022001013A (cg-RX-API-DMAC7.html)
PE (1) PE20221588A1 (cg-RX-API-DMAC7.html)
PH (1) PH12022550182A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021014386A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202201157B (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3847157T3 (da) * 2018-09-07 2022-08-08 Sanofi Sa Fremgangsmåde til fremstilling af methyl-[6-(2,4-dichlorphenyl)-5-[4-[(3s)-1-(3-fluorpropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulen-2-carboxylat] og salt deraf
US12391667B2 (en) 2019-07-22 2025-08-19 Boehringer Ingelheim International Gmbh N-methyl, n-(6-(methoxy)pyridazin-3-yl) amine derivatives as Autotaxin (ATX) modulators for the treatment of inflammatory airway or fibrotic diseases
US11014915B2 (en) * 2019-07-22 2021-05-25 Sun Pharma Advanced Research Company Limited Selective estrogen receptor degrader
PE20241731A1 (es) * 2022-02-01 2024-08-19 Lilly Co Eli Procesos para la preparacion de degradadores selectivos del receptor de estrogeno
CN119176799B (zh) * 2024-09-19 2025-10-03 晨伫(杭州)生物科技有限责任公司 色烯衍生物及其应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5395842A (en) 1988-10-31 1995-03-07 Endorecherche Inc. Anti-estrogenic compounds and compositions
DE69023906T2 (de) 1990-08-09 1996-04-11 Council Scient Ind Res Benzopyrane und Verfahren zu deren Herstellung.
US6060503A (en) 1991-12-02 2000-05-09 Endorecherche, Inc. Benzopyran-containing compounds and method for their use
US5407947A (en) 1993-11-05 1995-04-18 Eli Lilly And Company Methods for inhibiting bone loss using pyrolidine and piperidine substituted benzopyrans
US5389646A (en) 1993-12-30 1995-02-14 Zymogenetics, Inc. Methods for treatment and prevention of bone loss using 2,3-benzopyrans
AU8102398A (en) 1997-07-09 1999-02-08 Central Drug Research Institute (dl)-2,3-diaryl-2h-1-benzopyrans
DE10013782A1 (de) 2000-03-15 2001-10-18 Schering Ag 4-Fluoralkyl-2H-benzopyrane mit antiestrogener Wirksamkeit, Verfahren zu ihrer Herstellung, pharmazeutische Präparate, die diese enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln
EP3205648A1 (en) 2010-06-10 2017-08-16 Seragon Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof
EP2791132A4 (en) 2011-12-14 2015-08-05 Seragon Pharmaceuticals Inc ESTROGEN RECEPTOR MODULATORS AND USES THEREOF
BR112014014767A2 (pt) 2011-12-16 2017-06-13 Olema Pharmaceuticals Inc novos compostos de benzopirano, composições e usos dos mesmos
EA031077B1 (ru) 2013-06-19 2018-11-30 Серагон Фармасьютикалз, Инк. Модулятор рецептора эстрогена и его применения
WO2014203132A1 (en) 2013-06-19 2014-12-24 Olema Pharmaceuticals, Inc. Substituted benzopyran compounds, compositions and uses thereof
BR112015030595A2 (pt) * 2013-06-19 2017-07-25 Seragon Pharmaceuticals Inc moduladores de receptor de estrogênio de azetidina e usos dos mesmos
CN103879283B (zh) * 2014-03-10 2019-01-15 浙江吉利汽车研究院有限公司 一种电动车辆
CN107406433A (zh) * 2014-12-18 2017-11-28 豪夫迈·罗氏有限公司 用于治疗癌症的2,3‑二苯基色烯的衍生物
WO2016174551A1 (en) 2015-04-27 2016-11-03 Pfizer Inc. Anti-estrogenic compounds
JP6768711B2 (ja) 2015-05-26 2020-10-14 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 複素環式エストロゲン受容体モジュレーター及びその使用
US10865199B2 (en) * 2015-10-27 2020-12-15 Sun Pharma Advanced Research Company Limited Heterocyclic antiestrogens
US11014915B2 (en) * 2019-07-22 2021-05-25 Sun Pharma Advanced Research Company Limited Selective estrogen receptor degrader

Also Published As

Publication number Publication date
ZA202201157B (en) 2023-07-26
JP2022541938A (ja) 2022-09-28
CA3148592A1 (en) 2021-01-28
BR112022001285A2 (pt) 2022-03-22
WO2021014386A1 (en) 2021-01-28
MX2022001013A (es) 2022-02-22
US20210261534A1 (en) 2021-08-26
KR20220046586A (ko) 2022-04-14
US20210024504A1 (en) 2021-01-28
IL290036A (en) 2022-03-01
CN114302879A (zh) 2022-04-08
AU2020317099A1 (en) 2022-02-24
PH12022550182A1 (en) 2022-11-14
US11014915B2 (en) 2021-05-25
EP4003525A1 (en) 2022-06-01
CL2022000156A1 (es) 2022-11-18

Similar Documents

Publication Publication Date Title
CL2022000156A1 (es) Degradador selectivo del receptor de estrógeno
MX2021009569A (es) Procesos y compuestos.
PH12021550296A1 (en) Substituted indoles and methods of use thereof
UY38767A (es) Compuestos para el tratamiento de enfermedades y trastornos asociados con braf
MX392461B (es) Moduladores de receptores estrogénicos
UY32352A (es) Régimen de dosificación para un agonista de los receptores de s1p
EA201791239A1 (ru) ТЕТРАГИДРОПИРИДО[3,4-b]ИНДОЛОВЫЕ МОДУЛЯТОРЫ ЭСТРОГЕНОВЫХ РЕЦЕПТОРОВ И ИХ ПРИМЕНЕНИЕ
PH12021550381A1 (en) Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents
EA201792394A2 (ru) Производные 2-(2,4,5-замещенного анилино)пиримидина в качестве модуляторов egfr, полезных для лечения рака
ZA202301275B (en) Indole compounds as androgen receptor modulators
UY33118A (es) Indazoles aminotiazolona sustituidos como moduladores del receptor a relacionado con estrógenos
MX392906B (es) Derivados de bisfenol y su uso como moduladores de la actividad del receptor de androgeno.
PE20160050A1 (es) Inhibidores/ antiandrogenos novedosos de cyp17
MX378389B (es) Compuestos de bencimidazolona y benzotiazolona y su uso como moduladores del receptor ampa.
PH12021550839A1 (en) Therapeutic use of trigonal glucagon/glp-1/gip receptor agonist or conjugate thereof for liver disease
CL2019003249A1 (es) Protocolo mejorado para el tratamiento de nefritis lúpica.
SA520420768B1 (ar) مركبات بنزين سلفوناميد واستخدامها كعوامل علاجية
WO2019123482A8 (en) Pharmaceutical composition for the treatment of cancer
MX2022005749A (es) Inhibidores de egfr alostericos y metodos de uso de los mismos.
PH12020551297A1 (en) Compounds having s1p5 receptor agonistic activity
ECSP088878A (es) Proceso para la preparación de indazolil ureas que inhiben receptores de vanilloides del subtipo 1 (vr1)
MX2021007687A (es) Sales novedosas de degradadores selectivos de receptores de estrogeno.
NZ741384A (en) Dopamine d3 receptor antagonists having a morpholine moiety
MX369806B (es) Compuestos de indolona y su uso como moduladores del receptor ampa.
MX2017014145A (es) Moduladores selectivos de la actividad del receptor gpr55: derivados de cromenopirazol.